Abstract: An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.

Abstract: The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for treating sperm that comprises medium for mesenchymal stem cells. This composition for treating sperm is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for treating sperm is preferably a serum-free medium.

Abstract: The present invention provides an external composition superior in stability and use feeling. According to the present invention, an external composition is prepared which includes (A) at least one selected from the group consisting of an ascorbic acid and an ascorbic salt, (B) a diol having 3 carbon atoms, (C) at least one selected from the group consisting of a low-molecular-weight betaine, an organic acid salt, an inorganic acid salt, a basic amino acid, a basic amino acid salt, 3-O-ethylascorbic acid, and a 3-O-ethylascorbic acid salt, and (D) water, and a content of ethoxydiglycol of said composition is less than 30 mass %.

Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

Abstract: The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.

Abstract: The present invention relates to an ophthalmological composition containing zinc chloride (A) and a polyvinyl-based polymer compound (B).

Abstract: Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin. The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of citric acid, phosphoric acid, and a salt thereof (B).

Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of edetic acid, creatinine, and a salt thereof (B).

Abstract: The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.

Abstract: The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

Abstract: The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).

Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof and having a pH of 4.0 to 6.5.

Abstract: The present invention is a resin container having a multilayer structure including a first layer that comes into contact with liquid content and a second layer that is in contact with the first layer from an outer side of the first layer. The first layer includes a cyclic olefin copolymer and a linear low-density polyethylene resin, and the second layer includes a low-density polyethylene resin.

Abstract: An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.

Abstract: Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

Abstract: The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.